celecoxib has been researched along with zileuton in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (36.59) | 29.6817 |
| 2010's | 23 (56.10) | 24.3611 |
| 2020's | 3 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Bailly, F; Cotelle, P; Hénichart, JP; Mbemba, G; Mouscadet, JF; Pommery, J; Pommery, N; Queffélec, C | 1 |
| Abraham, WM; Albert, L; Behnke, ML; Chen, L; Clark, JD; Donahue, F; Foley, MA; Goodwin, DG; Hegen, M; Hu, B; Hu, Y; Ipek, M; Keith, J; Kirincich, SJ; Ku, MS; Lee, KL; McKew, JC; Michalak, R; Murphy, EA; Nickerson-Nutter, CL; Ramarao, MK; Shen, MW; Sum, FW; Tam, S; Thakker, P; Thomason, J; Williams, C; Wooder, L; Wu, K; Xu, X | 1 |
| Greiner, C; Koeberle, A; Schubert-Zsilavecz, M; Werz, O; Wurglics, M; Zettl, H | 1 |
| Chen, L; Clark, JD; Goodwin, DG; Lee, KL; McKew, JC; Murphy, EA; Nickerson-Nutter, C; Shen, MW; Tam, S; Wang, W; Xu, X; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Aparoy, P; Chandramohan Reddy, T; Kalangi, SK; Kumar Reddy, K; Reddanna, P | 1 |
| Bridoux, A; Henichart, JP; Millet, R; Pommery, J; Pommery, N | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Buscató, E; Deckmann, K; Geisslinger, G; Grösch, S; Proschak, E; Rörsch, F; Schneider, G; Schubert-Zsilavecz, M | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Barz, D; Dehm, F; Hanke, T; Kaiser, A; Kunze, J; Lämmerhofer, M; Liening, S; Maczewsky, J; Pillong, M; Popella, SD; Sautebin, L; Schneider, G; Schubert-Zsilavecz, M; Weinigel, C; Werz, O; Wurglics, M | 1 |
| Ferreiros, N; Geisslinger, G; Grösch, S; Hanke, T; Proschak, E; Rörsch, F; Schneider, G; Schubert-Zsilavecz, M; Thieme, TM | 1 |
| Barz, D; Bruno, F; de Caprariis, P; De Rosa, M; Dehm, F; Filosa, R; Krauth, V; Massa, A; Peduto, A; Weinigel, C; Werz, O | 1 |
| Bhatti, R; Dhillon, P; Prasher, P; Singh, P | 1 |
| Cai, H; Huang, X; Huang, Y; Jiang, B; Jiang, J; Shen, H; Sun, Y; Wu, X; Xu, J; Xu, S; Yao, H; Zhang, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bandresh, R; Shrivastava, SK; Srivastava, P; Tripathi, A; Tripathi, PN | 1 |
| Man, RJ; Ren, SZ; Shen, FQ; Wang, BZ; Wang, ZC; Wu, SY; Zhu, HL | 1 |
| Abdel-Ghany, YS; Alaaeddine, R; Alaeddine, LM; Belal, ASF; El-Yazbi, AF; Hazzaa, A; Ismail, A; Moussa, G; Nassra, R | 1 |
| Hu, C; Ma, S | 1 |
| Abu-Serie, MM; AlFadly, ED; Bakkar, NZ; Bartolini, M; Belal, ASF; El-Yazbi, AF; Elkazaz, S; Elzahhar, PA; Ghareeb, DA; Iriepa, I; Janockova, J; Kobeissy, F; Moraleda, I; Rafeh, RW; Saudi, MNS; Shaltout, H; Soukup, O; Tramarin, A | 1 |
| Abbas, M; Chen, PW; Duan, YT; Li, X; Li, Z; Liu, QX; Liu, Y; Lv, PC; Ren, SZ; Wang, ZC; Wu, SY; Zhu, HL | 1 |
| Narang, RK; Pathania, S; Rawal, RK | 1 |
| Abid, OU; Ahmad, A; Ahmad, S; Ayaz, M; Hussain, F; Jan, MS; Mahmood, F; Rashid, U; Sadiq, A; Ullah, F | 1 |
| Bhatti, R; Kaur, J; Kumari, P; Singh, P | 1 |
| Cui, E; Du, L; Du, S; Jiang, X; Li, J; Ma, X; Qian, S; Wang, H | 1 |
| Achucarro, P; Guski, H; Heinicken, D; Jacobi, CA; Kilian, M; Müller, JM; Schimke, I; Wenger, FA | 1 |
| Bisevac, M; Guski, H; Khodadayan, C; Kilian, M; Müller, JM; Schimke, I; von Seebach, M; Wenger, FA | 1 |
| Chacur, M; Cury, Y; Guerra, JL; Gutiérrez, JM; Lomonte, B; Longo, I; Picolo, G; Teixeira, CF | 1 |
| Fiorucci, S; Hollenberg, MD; von der Weid, PY; Wallace, JL | 1 |
| Beer, DG; Chen, X; Giordano, TJ; Jin, Z; Lin, Y; Lubet, RA; Shih, WC; Sood, S; Wang, P; Wang, S; Wu, N; Yang, CS | 1 |
| Chen, X; Fang, M; Li, N; Sood, S; Sun, Z; Wang, P; Wang, S; Yang, CS | 1 |
| Gregor, JI; Heukamp, I; Jacobi, CA; Kiewert, C; Kilian, M; Kristiansen, G; Schimke, I; Walz, MK; Wenger, FA | 1 |
| Hénichart, JP; Pommery, J; Pommery, N | 1 |
| Amann, JM; Backlund, MG; Johnson, DH | 1 |
| Bedor, M; Edelman, MJ; Gajra, A; Green, MJ; Hodgson, L; Jewell, S; Kratzke, RA; Masters, GA; Mauer, AM; Morrison, C; Vokes, EE; Wang, X; Watson, D | 1 |
| Fegn, L; Wang, Z | 1 |
| Horn, TL; Johnson, WD; Lubet, RA; McCormick, DL; Phillips, JM; Steele, VE | 1 |
| Akpa, EG; Bosworth, BP; Boyle, JO; Brown, PH; Dannenberg, AJ; Duffield-Lillico, AJ; Kingsley, PJ; Knutson, A; Marnett, LJ; Milne, GL; Mohebati, A; Szabo, E; Zhou, XK | 1 |
| Altavilla, D; Arcoraci, V; Bitto, A; Galfo, F; Irrera, N; Macrì, A; Minutoli, L; Pallio, G; Pizzino, G; Squadrito, F; Squadrito, G | 1 |
3 review(s) available for celecoxib and zileuton
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent development of lipoxygenase inhibitors as anti-inflammatory agents.
Topics: | 2018 |
Role of sulphur-heterocycles in medicinal chemistry: An update.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Antihypertensive Agents; Antineoplastic Agents; Chemistry, Pharmaceutical; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Sulfur | 2019 |
2 trial(s) available for celecoxib and zileuton
| Article | Year |
|---|---|
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Eicosanoids; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Immunohistochemistry; Lipoxygenase Inhibitors; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Up-Regulation | 2008 |
Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
Topics: Adult; Arachidonate 5-Lipoxygenase; Biomarkers; Celecoxib; Chromatography, Liquid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; Hydroxyurea; Leukotriene E4; Lipoxygenase Inhibitors; Male; Maximum Tolerated Dose; Prognosis; Prostaglandins; Pyrazoles; Smoking; Sulfonamides; Tandem Mass Spectrometry | 2013 |
36 other study(ies) available for celecoxib and zileuton
| Article | Year |
|---|---|
Synthesis and biological activities of a series of 4,5-diaryl-3-hydroxy-2(5H)-furanones.
Topics: Base Sequence; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; DNA Primers; Furans; HIV Integrase Inhibitors; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry | 2008 |
Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Benzoates; Biological Availability; Bronchoconstriction; Calorimetry; Carrageenan; Cell Line; Cyclooxygenase 2 Inhibitors; Edema; Group IV Phospholipases A2; Humans; In Vitro Techniques; Isoenzymes; Male; Mice; Protein Binding; Rats; Rats, Sprague-Dawley; Sheep; Structure-Activity Relationship; Sulfonamides | 2008 |
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
Topics: Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Cyclooxygenase 1; Cyclooxygenase 2; Drug Design; Enzyme Activation; Enzyme Inhibitors; Humans; Inflammation; Inhibitory Concentration 50; Intramolecular Oxidoreductases; Lipoxygenase Inhibitors; Models, Chemical; Prostaglandin-E Synthases; Pyrimidines | 2008 |
Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.
Topics: Animals; Enzyme Inhibitors; Group IV Phospholipases A2; Hydrophobic and Hydrophilic Interactions; Rats; Structure-Activity Relationship; Sulfides; Sulfonamides | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
Topics: Arachidonate 5-Lipoxygenase; Computer Simulation; Drug Design; Drug Evaluation, Preclinical; Lipoxygenase Inhibitors; Models, Chemical; Models, Molecular | 2010 |
Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Carbolines; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase Inhibitors; Humans; Indomethacin; Lipoxygenase Inhibitors; Male; Prostatic Neoplasms; Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Structure-activity relationship of nonacidic quinazolinone inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1).
Topics: Animals; Biological Availability; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; HeLa Cells; Humans; Intramolecular Oxidoreductases; Mice; Microsomes; Prostaglandin-E Synthases; Quinazolinones; Structure-Activity Relationship | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo.
Topics: Animals; Arachidonate 5-Lipoxygenase; Binding Sites; Drug Design; Humans; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Intramolecular Oxidoreductases; Lipoxygenase Inhibitors; Male; Mice; Microsomes; Models, Molecular; Peritonitis; Prostaglandin-E Synthases; Protein Conformation; Pyrimidines; Structure-Activity Relationship; Thiazoles; Zymosan | 2013 |
Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1.
Topics: Animals; Benzenesulfonamides; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; HeLa Cells; Humans; Intramolecular Oxidoreductases; Ligands; Mice; Molecular Structure; NIH 3T3 Cells; Prostaglandin-E Synthases; Structure-Activity Relationship; Sulfonamides | 2013 |
Further studies on ethyl 5-hydroxy-indole-3-carboxylate scaffold: design, synthesis and evaluation of 2-phenylthiomethyl-indole derivatives as efficient inhibitors of human 5-lipoxygenase.
Topics: Arachidonate 5-Lipoxygenase; Dose-Response Relationship, Drug; Drug Design; Humans; Indoles; Lipoxygenase Inhibitors; Molecular Structure; Structure-Activity Relationship | 2014 |
Indole based peptidomimetics as anti-inflammatory and anti-hyperalgesic agents: Dual inhibition of 5-LOX and COX-2 enzymes.
Topics: Animals; Anti-Inflammatory Agents; Catalytic Domain; Crystallography, X-Ray; Cyclooxygenase 2 Inhibitors; Hyperalgesia; Indoles; Inhibitory Concentration 50; Lipoxygenase Inhibitors; Mice; Molecular Docking Simulation; Molecular Structure; Peptidomimetics | 2015 |
Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Caffeic Acids; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Lipoxygenase Inhibitors; Lung Neoplasms; Molecular Structure; Structure-Activity Relationship; Triazoles | 2016 |
Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Carrageenan; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Edema; Female; Indolizines; Lipoxygenase; Lipoxygenase Inhibitors; Male; Mice; Molecular Structure; Prostaglandin-Endoperoxide Synthases; Rats; Structure-Activity Relationship; Ulcer | 2017 |
Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX.
Topics: A549 Cells; Apoptosis; Arachidonate 5-Lipoxygenase; Binding Sites; Catalytic Domain; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Coumarins; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Lipoxygenase Inhibitors; Molecular Docking Simulation; Pyrazoles; Structure-Activity Relationship | 2017 |
Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 15-Lipoxygenase; Cell Differentiation; Click Chemistry; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Female; Humans; Lipoxygenase Inhibitors; Macrophages; Molecular Docking Simulation; Molecular Structure; Quinazolinones; Rats; Rats, Wistar; Structure-Activity Relationship; Sulfhydryl Compounds; Tumor Cells, Cultured | 2018 |
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Inflammation; Lipoxygenase Inhibitors; Mice; Molecular Docking Simulation; Neurons; PC12 Cells; Rats; Semicarbazides; Triazoles | 2019 |
Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents.
Topics: Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Azoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Lipoxygenase Inhibitors; Models, Molecular; Molecular Structure; Morpholines; Structure-Activity Relationship | 2019 |
Design, synthesis, in-vitro, in-vivo and in-silico studies of pyrrolidine-2,5-dione derivatives as multitarget anti-inflammatory agents.
Topics: Albumins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Carrageenan; Cyclooxygenase 2; Dose-Response Relationship, Drug; Drug Design; Edema; Enzyme Inhibitors; Female; Humans; Male; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Molecular Structure; Pyrrolidines; Structure-Activity Relationship | 2020 |
Design, Synthesis, and Activity Evaluation of Stereoconfigured Tartarate Derivatives as Potential Anti-inflammatory Agents
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Edema; Female; Humans; Lipoxygenase; Lipoxygenase Inhibitors; Male; Mice; Molecular Structure; Stereoisomerism; Structure-Activity Relationship; Tartrates | 2021 |
Design and synthesis of novel indole and indazole-piperazine pyrimidine derivatives with anti-inflammatory and neuroprotective activities for ischemic stroke treatment.
Topics: Animals; Anti-Inflammatory Agents; Brain Ischemia; Cyclooxygenase 2; Disease Models, Animal; Indazoles; Indoles; Ischemic Stroke; Lipopolysaccharides; Mice; Microglia; Neuroprotection; Neuroprotective Agents; Piperazine; Pyrimidines; Rats; Stroke; Tumor Necrosis Factor-alpha | 2022 |
Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Celecoxib; Cricetinae; Glutathione; Hydroxyurea; Incidence; Lipoxygenase Inhibitors; Male; Mesocricetus; Pancreas; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2002 |
Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cricetinae; Hydroxyurea; Lipid Peroxidation; Lipoxygenase Inhibitors; Liver Neoplasms; Male; Mesocricetus; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2002 |
Hyperalgesia induced by Asp49 and Lys49 phospholipases A2 from Bothrops asper snake venom: pharmacological mediation and molecular determinants.
Topics: Animals; Bothrops; Bradykinin; Carrageenan; Celecoxib; Crotalid Venoms; Heparin; Hindlimb; Histamine Antagonists; Hydroxyurea; Hyperalgesia; Male; omega-N-Methylarginine; Peptides; Phospholipases A; Pyrazoles; Rats; Rats, Wistar; Serotonin Antagonists; Sulfonamides; Time Factors | 2003 |
Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone.
Topics: Acetylcholine; Animals; Aorta; Aspirin; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelium, Vascular; Hydroxyurea; Lipoxins; Lipoxygenase Inhibitors; Male; Mesenteric Arteries; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroarginine; Oligopeptides; Pyrazoles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Lipoxin; Sulfonamides; Vascular Resistance; Vasodilation; Vasodilator Agents | 2004 |
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Body Weight; Celecoxib; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esophageal Neoplasms; Humans; Hydroxyurea; Immunohistochemistry; Leukotriene B4; Lipoxygenase Inhibitors; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2004 |
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Carcinogens; Carcinoma, Squamous Cell; Celecoxib; Cell Transformation, Neoplastic; Chemoprevention; Cricetinae; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Humans; Hydroxyurea; Immunohistochemistry; In Situ Hybridization; Lipoxygenase Inhibitors; Male; Membrane Proteins; Mesocricetus; Mouth Neoplasms; Neoplasms, Experimental; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Up-Regulation | 2005 |
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.
Topics: Animals; Carcinoma, Pancreatic Ductal; Celecoxib; Cricetinae; Cyclooxygenase Inhibitors; Dinoprostone; Drug Therapy, Combination; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Liver; Liver Neoplasms; Pancreas; Pancreatic Neoplasms; Prostaglandins; Prostaglandins F; Pyrazoles; Sulfonamides | 2005 |
Modification of eicosanoid profile in human blood treated by dual COX/LOX inhibitors.
Topics: Arachidonic Acid; Calcimycin; Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Eicosanoids; Humans; Hydroxyurea; Indomethacin; Inhibitory Concentration 50; Lipopolysaccharides; Lipoxygenase Inhibitors; Pyrazoles; Sulfonamides | 2005 |
Novel strategies for the treatment of lung cancer: modulation of eicosanoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Eicosanoids; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Lung Neoplasms; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Up-Regulation | 2008 |
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.
Topics: Administration, Topical; Analysis of Variance; Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Combinations; Head and Neck Neoplasms; Hydroxyurea; Lipoxygenase Inhibitors; Mice; Mice, Nude; Pyrazoles; Random Allocation; Skin Neoplasms; Sulfonamides | 2009 |
Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Gene Expression; Hydroxyurea; Lipoxygenase Inhibitors; Male; Mouth Neoplasms; Naproxen; Piroxicam; Pyrazoles; Rats; Rats, Inbred F344; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Up-Regulation | 2010 |
Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Body Weight; Catechin; CD3 Complex; Celecoxib; Colitis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Combinations; Eating; Gene Expression Regulation; Hydroxyurea; Leukotriene B4; Lipid Peroxidation; Lipoxygenase Inhibitors; Male; Neutrophil Infiltration; Rats; Rats, Sprague-Dawley; Thromboxane B2; Tumor Necrosis Factor-alpha | 2016 |